BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther 2020;37:364-80. [PMID: 31748904 DOI: 10.1007/s12325-019-01145-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Bykerk VP, Blauvelt A, Curtis JR, Gaujoux-Viala C, Kvien TK, Winthrop K, Tilt N, Popova C, Mariette X, Haraoui B. Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. ACR Open Rheumatol 2021;3:501-11. [PMID: 34196507 DOI: 10.1002/acr2.11259] [Reference Citation Analysis]
2 Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Peltomaa R, Aaltonen K, Trokovic N, Kristianslund EK, Kvien TK, Provan SA, Gudbjornsson B, Grondal G, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson LTH, Askling J. Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. J Rheumatol 2021;48:1512-8. [PMID: 33649069 DOI: 10.3899/jrheum.201467] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Barroso DH, Brandão JG, Andrade ESN, Correia ACB, Aquino DC, Chen ACR, Vernal S, de Araújo WN, da Mota LMH, Sampaio RNR, Kurizky PS, Gomes CM. Leprosy detection rate in patients under immunosuppression for the treatment of dermatological, rheumatological, and gastroenterological diseases: a systematic review of the literature and meta-analysis. BMC Infect Dis 2021;21:347. [PMID: 33849463 DOI: 10.1186/s12879-021-06041-7] [Reference Citation Analysis]
4 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
5 Coste N, Bocquet A, Labarere J, Semecas R, Aptel F, Deroux A, Bouillet L, Chiquet C. Tolerance and efficacy of anti-TNF currently used for severe non-infectious uveitis. Autoimmun Rev 2021;20:102752. [PMID: 33476820 DOI: 10.1016/j.autrev.2021.102752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang YC, Feng YT, Lin YC, Lee CT, Tung TH. Effect of adalimumab interventions on general infection among adults: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-17. [PMID: 33703989 DOI: 10.1080/14787210.2021.1902804] [Reference Citation Analysis]
7 Zhao L, Zhang X, Zhu L, Geng S, Guo K. Effectiveness and safety of Adalimumab in psoriasis and its influence on gut microbiome. Microb Pathog 2021;162:105308. [PMID: 34843923 DOI: 10.1016/j.micpath.2021.105308] [Reference Citation Analysis]
8 Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial. Arthritis Res Ther 2021;23:248. [PMID: 34563243 DOI: 10.1186/s13075-021-02626-4] [Reference Citation Analysis]
9 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
10 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
11 Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opin Drug Saf 2020;19:381-93. [PMID: 32098513 DOI: 10.1080/14740338.2020.1734560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kim KS, Choi YH, Moon A, Kim SG. Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting. J Clin Med 2020;9:E461. [PMID: 32046138 DOI: 10.3390/jcm9020461] [Reference Citation Analysis]
13 Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol 2021;48:1230-8. [PMID: 33526618 DOI: 10.3899/jrheum.201183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf 2020;19:807-16. [PMID: 32441228 DOI: 10.1080/14740338.2020.1773430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 2022. [PMID: 35503130 DOI: 10.1007/s00296-022-05136-x] [Reference Citation Analysis]
16 Croft NM, Faubion WA Jr, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, Mostafa NM, Venetucci M, Finney-Hayward T, Sanchez Gonzalez Y, Bereswill M, Lazar A, Turner D. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol 2021;6:616-27. [PMID: 34153231 DOI: 10.1016/S2468-1253(21)00142-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tachkov K, Mitkova Z, Boyadzieva V, Petrova G. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. Pharmaceuticals (Basel) 2021;14:64. [PMID: 33466766 DOI: 10.3390/ph14010064] [Reference Citation Analysis]
18 Yang Y, Xie S, Jiang W, Tang S, Shi Y. Discovering Novel Biomarkers Associated with the Pathogenesis of Psoriasis: Evidence from Bioinformatic Analysis. IJGM 2022;Volume 15:2817-33. [DOI: 10.2147/ijgm.s354985] [Reference Citation Analysis]
19 Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
20 Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther 2022;24:73. [PMID: 35313978 DOI: 10.1186/s13075-022-02753-6] [Reference Citation Analysis]
21 Maccora I, dell’Anna MP, Vannacci A, Simonini G. Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert Opinion on Drug Safety 2020;19:661-71. [DOI: 10.1080/14740338.2020.1763300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV, Tan H, Madsen A, Valdez H, Cohen SB. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open 2021;7:e001595. [PMID: 34045358 DOI: 10.1136/rmdopen-2021-001595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]